Glenmark Pharmaceuticals is planning to launch a Phase 1 trial in solid tumors for its CD38xCD3 bispecific antibody GBR 1342. The decision is driven by recent findings derived from a non-interventional human study utilizing a clinically validated CAN script platform.
GBR 1342 is based on Glenmark’s proprietary BEAT platform and simultaneously targets CD38 and the CD3 T cell co-receptor. CD38 is an antigen known to be implicated in hematological malignancies as well as some solid tumors. The company intends to file an Investigational New Drug (IND) application for GBR 1342 in solid tumors and initiate a clinical trial in 2019.
Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).